CYTK

Cytokinetics Inc

Approval AI-extracted

MYQORZO

obstructive hypertrophic cardiomyopathy

Resolved

188days ago

Approval decision · ~ Dec 31, 2025 estimated

What's at stake A final FDA approval decision on MYQORZO for obstructive hypertrophic cardiomyopathy is expected ~ Dec 31, 2025.

Primary source · SEC 8-K verified 15h ago

“Received approval in December from the U.S. Food and Drug Administration (FDA) for MYQORZO ( aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).”

Add to calendar Post on X Reddit

Provenance